Online citations, reference lists, and bibliographies.
← Back to Search

Current Status And Future Prospects Of Parenteral Insulin Regimens, Strategies And Delivery Systems For Diabetes Treatment.

Jeandidier, Boivin
Published 1999 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
A strong relationship between long term metabolic control and low frequency of chronic diabetes complications was shown in the Diabetes Control Complication Trial (DCCT). However, the subcutaneous intensive insulin therapy required to achieve the glycemic goals defined by the DCCT led to an unacceptable frequency of severe hypoglycemia and a significant weight gain. This limits the benefits of this therapy and excludes groups of patients such as young children, the elderly or hypoglycemia prone patients. The intensive therapy and self blood glucose monitoring (SMBG) necessary to limit hypoglycemia represent a heavy burden for the patients and their family. Improvements in parenteral insulin therapy are possible by either modifying subcutaneous insulin characteristics (analogs, adjunction of peptides such as amylin, GLP1, IGF1), or by developing better routes of administration and making SMBG easier, which is a key to intensive insulin therapy success. The ultimate goal remains the development of an automated, glucose controlled device.
This paper references
10.1210/JCEM.77.3.8370695
Peritoneal and subcutaneous absorption of insulin in type I diabetic subjects.
A. Giacca (1993)
10.1016/0168-8227(94)90036-1
Influence of intensified insulin regimen on quality of life and metabolic control in insulin-dependent diabetes mellitus.
B. Karlson (1994)
10.2337/diacare.15.7.877
Clinical Trial of Programmable Implantable Insulin Pump For Type I Diabetes
J. Selam (1992)
10.1007/s001250051416
Are presently available insulin analogues clinically beneficial?
M. Berger (1997)
10.2337/diacare.17.11.1295
Intraperitoneal Insulin Delivery Decreases the Levels of Chylomicron Remnants in Patients With IDDM
A. Georgopoulos (1994)
10.1055/S-2007-978916
Long term safety and efficacy of intraperitoneal insulin infusion by means of implantable pumps.
M. Pinget (1998)
10.1007/BF02446259
Insulin dosage adjustment using manual methods and computer algorithms: A comparative study
A. Albisser (2006)
10.1177/039139889301600903
Artificial pancreas, glucose sensors and the impact upon diabetology.
Pfeiffer Ef (1993)
10.2337/diacare.18.3.388
Feasibility of Intraperitoneal Insulin Therapy With Programmable Implantable Pumps in IDDM: A multicenter study
H. Hanaire-Broutin (1995)
10.2337/diacare.13.11.1135b
Influence of Insulin Pen Injection Frequency on Quality of Life
P. Andersson (1990)
10.1210/JC.81.5.1975
The degree/rapidity of the metabolic deterioration following interruption of a continuous subcutaneous insulin infusion is influenced by the prevailing blood glucose Level.
M. Castillo (1996)
10.2337/diacare.17.8.941b
Intraperitoneal Insulin Administration Does Not Modify Plasminogen Activator Inhibitor 1 Levels in IDDM Patients
D. Raccah (1994)
10.2337/diacare.20.3.433
Noninvasive Blood Glucose Monitoring
D. Klonoff (1997)
10.2337/diacare.20.9.1426
Dermal Interstitial Glucose as an Indicator of Ambient Glycemia
F. J. Service (1997)
10.1016/0197-0070(91)90050-V
Use of the pen delivery system for intensive insulin therapy in college-age students with type I diabetes.
H. Chase (1991)
10.2337/diacare.18.4.498
Immunogenicity of Long-Term Intraperitoneal Insulin Administration With Implantable Programmable Pumps: Metabolic consequences
V. Lassmann-Vague (1995)
Pompes à insuline
V. Lassmann-Vague (1995)
10.2337/diacare.20.12.1874
GLP-1 Tablet in Type 2 Diabetes in Fasting and Postprandial Conditions
M. Gutniak (1997)
10.1016/S0733-8635(18)30549-7
Pressure dermatitis from an implanted pacemaker.
M. G. Wilkerson (1990)
10.1016/0168-8227(92)90119-C
Is the reuse of needles for insulin injection systems associated with a higher risk of cutaneous complications?
G. Schuler (1992)
10.2337/diab.44.6.626
Glucagon-Like Peptide I Reduces Postprandial Glycemic Excursions in IDDM
J. Dupré (1995)
10.1016/S0738-3991(96)00964-0
Effect of patient-selected intensive insulin therapy on quality of life.
E. Chantelau (1997)
10.2337/diacare.18.8.1113
Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes (VA CSDM): Results of the feasibility trial
C. Abraira (1995)
[The insulin pen injector: toward its rational development and utilization].
H. Leblanc (1993)
10.1016/S0026-0495(96)90215-2
Intraperitoneal insulin infusion improves the depletion in choline-containing phospholipids of lipoprotein B particles in type I diabetic patients.
B. Guerci (1996)
10.2337/diacare.16.9.1306
Quality Control in Patient Self-Monitoring of Blood Glucose
J. Greyson (1993)
10.1055/S-2007-1001725
SHBG (sex hormone binding globulin) levels in insulin dependent diabetic patients according to the route of insulin administration.
V. Lassmann-Vague (1994)
10.1016/0168-8227(94)90258-5
Artificial endocrine pancreas and optimal blood glucose regulation in diabetic patients--from bedside-type to wearable-type.
M. Shichiri (1994)
10.2337/diacare.18.3.300
Catheter Complications Associated With Implantable Systems for Peritoneal Insulin Delivery: An analysis of frequency, predisposing factors, and obstructing materials
E. Renard (1995)
10.2337/diacare.19.7.780
Decreased Severe Hypoglycemia Frequency During Intraperitoneal Insulin Infusion Using Programmable Implantame Pumps
N. Jeandidier (1996)
Effect of multiple insulin injections with a pen injector on metabolic control and general well-being in insulin-dependent diabetes mellitus.
M. A. Gall (1989)
10.2337/diacare.18.1.56
Intraperitoneal Insulin Absorption After Lona-Term Intraperitoneal Insulin Therapy
M. Scavini (1995)
10.1016/S0958-1669(96)80093-0
Non-invasive glucose monitoring.
M. Arnold (1996)
10.1001/JAMA.276.16.1322
Implantable insulin pump vs multiple-dose insulin for non-insulin-dependent diabetes mellitus: a randomized clinical trial. Department of Veterans Affairs Implantable Insulin Pump Study Group.
C. Saudek (1996)
10.1007/s001250051417
Alternative insulin delivery systems: how demanding should the patient be?
K. Polonsky (1997)
10.1046/j.1365-2796.1996.19841000.x
C‐peptide revisited – new physiological effects and therapeutic implications
J. Wahren (1996)
10.2337/diacare.17.1.50
Dietary Fat Predicts Conversion From Impaired Glucose Tolerance to NIDDM: The San Luis Valley Diabetes Study
J. Marshall (1994)
10.2337/diab.46.4.632
Effects of Pramlintide, an Analog of Human Amylin, on Plasma Glucose Profiles in Patients With IDDM: Results of a Multicenter Trial
R. G. Thomas (1997)
10.2337/diacare.16.3.122
Future Developments in Insulin Delivery Systems
C. Saudek (1993)
10.1152/AJPENDO.1995.269.6.E1115
A model for multiple subcutaneous insulin injections developed from individual diabetic patient data.
W. Puckett (1995)
10.1016/0026-0495(81)90164-5
The kinetics of peritoneal insulin absorption.
D. Schade (1981)
10.2337/diacare.17.8.847
A Cost-Benefit Comparison of Intensive Diabetes Management With Implantable Pumps Versus Multiple Subcutaneous Injections in Patients With Type I Diabetes
M. Haardt (1994)
10.2337/diacare.19.1.90a
Severe Autonomic Neuropathy Treated With Subcutaneous Insulin Infusion
J. J. Prendergast (1996)
10.2337/diacare.20.9.1396
Excess Costs of Medical Care for Patients With Diabetes in a Managed Care Population
J. Selby (1997)
10.2337/diacare.17.1.92
Insulin-Like Growth Factor I Therapy for Diabetes Mellitus?
J. Kolaczynski (1994)
10.2337/diacare.19.4.324
Reduction in Severe Hypoglycemia With Long-Term Continuous Subcutaneous Insulin Infusion in Type I Diabetes
B. Bode (1996)
10.1055/S-2007-1001751
Implantation of non-toxic materials from glucose sensors: evidence for specific antibodies detected by ELISA.
M. Schlosser (1994)
10.2337/diacare.19.8.812
Insulin Underdelivery From Implanted Pumps Using Peritoneal Route: Determinant role of insulin pump compatibility
E. Renard (1996)
10.1109/SENSOR.1995.717235
Non-invasive Blood Glucose Monitoring
T. Kuriyama (1995)
10.1177/039139889501800605
Multicentre Trial of a Programmable Implantable Insulin Pump in Type I Diabetes
M. Pinget (1995)
10.2337/diacare.20.12.1847
The Cost to Health Plans of Poor Glycemic Control
T. Gilmer (1997)
10.1177/089686089601601S54
Subcutaneous and Intraperitoneal Insulin Therapy in Diabetic Patients on Capd
P. Nevalainen (1996)
Short-term treatment by implantable pump does not impair lipoprotein pattern in IDDM patients.
H. Hanaire-Broutin (1992)
10.2337/diacare.19.3.255
Human Insulin-Induced Lipoatrophy: Successful treatment using a jet-injection device
S. Logwin (1996)
10.1111/J.1464-5491.1993.TB00126.X
Severe Lipoatrophy with Human Insulin: Successfully Treated by CSII
E. Chantelau (1993)
10.1177/089686089601601S51
Peritoneal Dialysis in Diabetics. Optimal Insulin Therapy on Capd: Intraperitoneal versus Subcutaneous Treatment
L. Scarpioni (1996)
10.1016/0196-6553(89)90172-7
Evaluation of the insulin jet injector as a potential source of infection.
J. Price (1989)
10.1007/s001250050604
Effect of intraperitoneal insulin delivery on growth hormone binding protein, insulin-like growth factor (IGF)-I, and IGF-binding protein-3 in IDDM
H. Hanaire-Broutin (1996)
10.1016/0168-8227(95)01044-E
Continuous subcutaneous insulin infusion (CSII) in children and adolescents with chronic poorly controlled type 1 diabetes mellitus.
B. S. Steindel (1995)
10.2337/diacare.13.11.1136
Insulin Pens in Elderly Diabetic Patients
K. Reinauer (1990)
10.2337/diacare.4.2.311
Algorithms for Adjustment of Insulin Dosage by Patients Who Monitor Blood Glucose
J. Skyler (1981)
10.1111/j.1464-5491.1988.tb00959.x
The Medi‐Jector II: Efficacy and Acceptability in Insulin‐dependent Diabetic Patients With and Without Needle Phobia
C. M. G. J. Houtzagers (1988)
10.1007/BF00280891
Chemical stability of insulin in a delivery system environment
U. Grau (2004)
10.1002/BJS.1800820103
Pathogenesis and prevention of adhesion formation
J. N. Thompson (1998)
10.2337/diab.46.9.1453
rhIGF-I Administration Reduces Insulin Requirements, Decreases Growth Hormone Secretion, and Improves the Lipid Profile in Adults With IDDM
P. Carroll (1997)
10.2337/diacare.18.6.888
Five Cases off Hyperthyroidism in Type I Diabetic Patients Treated With Intraperitoneal Insulin Infusion
N. Jeandidier (1995)
10.2337/diacare.17.1.6
Normalization of Lipoprotein Composition by Intraperitoneal Insulin in IDDM: Role of increased hepatic lipase activity
G. Ruotolo (1994)
10.1016/0929-693X(96)81717-9
Disparition des accidents hypoglycémiques sévères chez le très jeune enfant diabétique traité par pompe sous-cutanée
N. Tubiana-Rufi (1996)
10.1007/s001250051412
Intensive insulin therapy in clinical practice
P. Home (1997)
10.1055/S-2007-1001752
Combination of microdialysis and glucose sensor for continuous on line measurement of the subcutaneous glucose concentration: theory and practical application.
C. Meyerhoff (1994)
10.2337/diacare.17.8.942
Alteration of the Risk Factor Paradigm for Discontinuance of Insulin Pump Therapy
R. Wredling (1994)
10.2337/diacare.17.3.169
Insulin Antibody Responses After Long-Term Intraperitoneal Insulin Administration via Impiantatile Programmable Insulin Delivery Systems
C. Olsen (1994)
10.2337/diab.39.11.1361
Determination of Portal Insulin Absorption From Peritoneum via Novel Nonisotopic Method
J. Selam (1990)
10.2337/diab.45.9.1253
Early Atherosclerosis Is Retarded by Improved Long-Term Blood Glucose Control in Patients With IDDM
K. Jensen-Urstad (1996)
10.1016/0026-0495(90)90025-8
Effects of intraperitoneal versus subcutaneous insulin administration on lipoprotein metabolism in type I diabetes.
G. Ruotolo (1990)
10.2337/diacare.16.11.1479
Jet-Injected Insulin Is Associated With Decreased Antibody Production and Postprandial Glucose Variability When Compared With Needle-Injected Insulin in Gestational Diabetic Women
L. Jovanovic-Peterson (1993)
10.1161/01.ATV.14.12.1933
Intraperitoneal insulin therapy corrects abnormalities in cholesteryl ester transfer and lipoprotein lipase activities in insulin-dependent diabetes mellitus.
J. Bagdade (1994)
10.2337/diab.36.7.838
Antibodies to Covalent Aggregates of Insulin in Blood of Insulin-Using Diabetic Patients
D. Robbins (1987)
10.1007/s001250051418
Advances and prospects in glucose assay technology
D. Gough (1997)
10.3109/14639239509024285
Application of computers in diabetes care--a review. II. Computers for decision support and education.
E. D. Lehmann (1995)
10.1111/j.1464-5491.1988.tb01054.x
NPH Insulin Administration by Means of a Pen Injector
J. Jørgensen (1988)
Comparison of intraperitoneal insulin infusion (using implantable pump) and subcutaneous insulin administration: preliminary results of a crossover study.
N. Jeandidier (1992)
10.7326/0003-4819-92-1-59
Alterations in insulin absorption and in blood glucose control associated with varying insulin injection sites in diabetic patients.
V. A. Koivisto (1980)
10.2337/diacare.15.1.19
Normalization of Composition of Triglyceride-Rich Lipoprotein Subfractions in Diabetic Subjects During Insulin Infusion With Programmable Implantable Medication System
A. Georgopoulos (1992)
Postoperative peritoneal adhesions. A study of the mechanisms.
G. Ryan (1971)
Evidence of non-inert material in needles and cartridges following a single insulin injection with a pen.
J. Le Floch (1997)
10.1126/SCIENCE.277.5325.563
Prevention of vascular and neural dysfunction in diabetic rats by C-peptide.
Y. Ido (1997)
10.2337/diacare.17.10.1235
Severe or Life-Threatening Hypoglycemia in Insulin Pump Treatment
K. Midthjell (1994)
10.2337/diab.46.3.440
Insulin Lispro in CSII: Results of a Double-Blind Crossover Study
B. Zinman (1997)
10.1016/0026-0495(94)90112-0
Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery.
J. Selam (1994)
10.1016/0026-0495(89)90240-0
Comparison of intraperitoneal and subcutaneous insulin administration on lipids, apolipoproteins, fuel metabolites, and hormones in type I diabetes mellitus.
J. Selam (1989)
10.2337/diacare.16.3.155
Immunogenicity and Allergenic Potential of Animal and Human Insulins
G. Schernthaner (1993)
10.1016/S0140-6736(94)91462-1
French multicentre experience of implantable insulin pumps
C. Broussolle (1994)



This paper is referenced by
Nanoengineered implantable devices for controlled drug delivery
Piyush M. Sinha (2005)
10.1016/S1359-6446(01)01962-6
Insulin therapies - past, present and future.
O. Pillai (2001)
10.4103/0250-474X.42968
Recent Challenges in Insulin Delivery Systems: A Review
M. Al-Tabakha (2008)
10.1002/dmrr.286
Challenges in optimal metabolic control of diabetes
A. Liebl (2002)
10.1002/ADFM.201001762
Nanotechnology‐Enabled Closed Loop Insulin Delivery Device: In Vitro and In Vivo Evaluation of Glucose‐Regulated Insulin Release for Diabetes Control
C. Gordijo (2011)
10.12968/BJON.2003.12.19.11801
A history of insulin: from discovery to modern alternatives.
K. King (2003)
10.3109/10611860903302815
Design of oral insulin delivery systems
T. Wong (2010)
10.1039/c6nr07818d
NIR upconversion fluorescence glucose sensing and glucose-responsive insulin release of carbon dot-immobilized hybrid microgels at physiological pH.
H. Wang (2017)
10.1517/17425247.3.3.379
Controlled-release microchips
S. Sharma (2006)
10.1211/00223570290
Covalent coupling of concanavalin A to a Carbopol 934P and 941P carrier in glucose‐sensitive gels for delivery of insulin
S. Tanna (2002)
Development of responsive polymers for drug delivery applications
Ian Benzeval (2009)
10.1016/S1262-3636(11)70967-3
How technology has changed diabetes management and what it has failed to achieve.
L. Ratheau (2011)
10.1081/DDC-120018644
Potential Applications of Polymeric Microsphere Suspension as Subcutaneous Depot for Insulin
D. Shenoy (2003)
10.1016/j.talanta.2017.11.037
Dual-responsive electrochemical immunosensor for detection of insulin based on dual-functional zinc silicate spheres-palladium nanoparticles.
Y. Li (2018)
10.1002/DDR.10426
Recent strategies and methods for improving insulin delivery
C. Lin (2004)
10.1016/J.MEDNUC.2010.07.002
Insulinothérapie : insuline ou analogues ? Injection ou perfusion ? Boucle ouverte ou boucle fermée ?
D. de la Haye Saint Hilaire (2010)
10.1016/S0378-6080(03)80049-1
Insulin, glucagon, and hypoglycemic drugs
H. Krans (2003)
10.1109/DTIP.2003.1287055
Design and fabrication of a peristaltic micropump
M. Knight (2003)
10.1007/978-0-387-25844-7_15
Nanoporous Implants for Controlled Drug Delivery
T. Desai (2006)
10.1021/nn401617u
Glucose-responsive microgels integrated with enzyme nanocapsules for closed-loop insulin delivery.
Z. Gu (2013)
10.2337/DIACARE.25.1.84
Comparison of antigenicity of Hoechst 21PH insulin using either implantable intraperitoneal pump or subcutaneous external pump infusion in type 1 diabetic patients.
N. Jeandidier (2002)
10.1039/C4RA08515A
Liposomal nanohybrid cerasomes for controlled insulin release
Y. Jin (2014)
10.1089/DIA.2005.7.612
Invasiveness as a barrier to self-monitoring of blood glucose in diabetes.
J. Wagner (2005)
10.1021/acsnano.6b06892
H2O2-Responsive Vesicles Integrated with Transcutaneous Patches for Glucose-Mediated Insulin Delivery.
X. Hu (2017)
10.1016/S0304-4165(03)00116-8
Polysialylated insulin: synthesis, characterization and biological activity in vivo.
S. Jain (2003)
10.1002/lsm.22608
Skin pre‐ablation and laser assisted microjet injection for deep tissue penetration
H. Jang (2017)
10.1016/j.msec.2018.11.032
Engineering synthetic artificial pancreas using chitosan hydrogels integrated with glucose-responsive microspheres for insulin delivery.
R. Yin (2019)
Glucose-responsive Implantable Polymeric Microdevices for “Smart” Insulin Therapy of Diabetes
M. Chu (2014)
10.1142/S1793545818500323
In vivo monitoring of microneedle-based transdermal drug delivery of insulin
Jiawei Zhao (2018)
10.1016/j.ijpharm.2009.06.014
Biopharmaceutical characterisation of insulin and recombinant human growth hormone loaded lipid submicron particles produced by supercritical gas micro-atomisation.
S. Salmaso (2009)
10.1080/1061186021000001869
A Covalently Stabilised Glucose Responsive Gel Formulation with a Carbopol ® Carrier
S. Tanna (2002)
10.1201/b18990-226
Protein Delivery Systems
N. Peppas (2006)
See more
Semantic Scholar Logo Some data provided by SemanticScholar